• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SunLink Health Systems Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits (Amendment)

    5/23/24 10:05:40 AM ET
    $SSY
    Hospital/Nursing Management
    Health Care
    Get the next $SSY alert in real time by email
    8-K/A
    NONE0000096793true--06-30true0000096793us-gaap:RightsMember2024-05-102024-05-1000000967932024-05-102024-05-100000096793us-gaap:CommonStockMember2024-05-102024-05-10

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K/A

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): May 10, 2024

     

    SunLink Health Systems Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Georgia 001-12607 31-0621189

    (State or Other Jurisdiction (Commission (I.R.S. Employer

    of Incorporation) File Number) Identification No.)

     

    900 Circle 75 Parkway

    Suite 690

    Atlanta, Georgia 30339

    (Address of Principal Executive Offices, and Zip Code)

     

    (770) 933-7000

    (Registrant’s telephone number, including area code)

     

    Not applicable.

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     


     

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, no par value

    SSY

    NYSE American

    Preferred Share Purchase Rights

     

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Item 5.03.

    Amendment to Bylaws; Item 3.03 Material Modification to Rights of Security Holders .

    As previously reported, on May 10, 2024, the Board of Directors (the “Board”) of SunLink Health Systems, Inc. (the “Company”) adopted the Company’s Amended and Restated Bylaws (the “Bylaws”) for the purpose of adding a new Section 2.15 to the Company’s pre-existing bylaws.

    Section 2.15 of the Bylaws sets forth the procedures that a shareholder must follow in order to submit a proposal of business for a shareholder vote or to nominate a person for election to the Board at an annual or special meeting of shareholders. Set forth below is a summary of these procedures.

    Notice Requirements for Shareholder Proposals (Excluding Director Nominations). Section 2.15(a) of the Bylaws provides that no proposal for a shareholder vote (other than director nominations which are described below) shall be submitted by a shareholder (a “Shareholder Proposal”) to the Company’s shareholders unless the shareholder submitting such proposal (the “Proponent”) shall have filed a written notice which includes, among other things:

    (i) the name and business address of the Proponent (including each beneficial owner, if any, on whose behalf the Shareholder Proposal is being made) and all Persons (as defined in Section 2.15(a) of the Bylaws) acting in concert with the Proponent (or such beneficial owner), and the name and address of all of the foregoing as they appear on the Company’s books (if they so appear);

    (ii) the class and number of shares of the Company that are owned beneficially and of record by the Proponent (including each beneficial owner, if any, on whose behalf the Shareholder Proposal is being made) and the other Persons identified in clause (i);

    (iii) a description of the Shareholder Proposal containing all material information relating thereto, including the information identified in Section 2.15(a)(iv) of the Bylaws;

    (iv) a description of any agreement, arrangement or understanding with respect to the Shareholder Proposal between or among the Proponent and each beneficial owner, if any, on whose behalf the Shareholder Proposal is being made, any of their respective affiliates or associates, and any others acting in concert with any of the foregoing;

    (v) a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, warrants, convertible securities, stock appreciation or similar rights, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of such written notice by, or on behalf of, the Proponent and each beneficial owner, if any, on whose behalf the Shareholder Proposal is being made, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of, the Proponent or such beneficial owner, with respect to the Company’s securities;

    (vi) a representation that the Proponent is a holder of record of the capital stock of the Company entitled to vote at the meeting, will so remain at the time of the meeting, and intends to appear in person or by proxy at the meeting to propose such business;

    (vii) a representation whether the Proponent or any beneficial owner on whose behalf the Shareholder Proposal is being made intends or is part of a group which intends (a) to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Company’s outstanding capital stock required to approve or adopt the Shareholder Proposal or (b) otherwise to solicit proxies from shareholders in support of such Shareholder Proposal; and

    (viii) any other information relating to the Proponent and such beneficial owner, if any, required to be disclosed in a proxy statement or other filing in connection with solicitations of proxies for the Shareholder Proposal under Section 14(a) of the Exchange Act.

    The notice shall also include such other information as the Board reasonably determines is necessary or appropriate to enable it and the shareholders of the Company to consider the Shareholder Proposal. The information

     


     

    required by clauses (ii), (iv) and (v) above must be updated by the Proponent and each beneficial owner, if any, on whose behalf the Shareholder Proposal is being submitted not later than ten days following the record date for the meeting to disclose such information as of the record date.

    The presiding officer at any shareholders’ meeting may determine that any Shareholder Proposal was not made in accordance with procedures prescribed by the Bylaws or otherwise is not in accordance with law, and if it is so determined, such officer will declare so at the meeting and the Shareholder Proposal will be disregarded. No provision of the Bylaws shall affect any rights of a shareholder to request inclusion of proposals in the Company’s proxy statement pursuant to Rule 14a-8 under the Exchange Act.

    Notice Requirements for Director Nominations. Section 2.15(b) of the Bylaws provides that only persons who are selected and recommended by the Board or the committee of the Board designated to make nominations, or who are nominated by shareholders in accordance with the procedures set forth in such section, shall be eligible for election, or qualified to serve, as directors. Nominations of individuals for election to the Board at any annual meeting or any special meeting of shareholders at which directors are to be elected may be made by any shareholder of the Company entitled to vote for the election of directors at that meeting by compliance with the procedures set forth in Section 2.15(b) of the Bylaws.

    Nominations by shareholders shall be made by written notice (a “Nomination Notice”), which, as to each individual nominated, shall set forth, among other things: (i) the name, date of birth, business address and residence address of such individual; (ii) the educational background and the business experience during the past five years of such nominee, including the information identified in Section 2.15(b) of the Bylaws; (iii) whether the nominee is or has ever been at any time a director, officer or owner of 5% or more of any class of capital stock, partnership interests or other equity interest of any corporation, partnership or other entity; (iv) any directorships held by such nominee in any public reporting company or any company registered as an investment company under the Investment Company Act of 1940; (v) whether such nominee has ever been convicted in a criminal proceeding or has ever been subject to a judgment, order, finding or decree in the proceedings described in Section 2.15(b) of the Bylaws; (vi) information regarding whether such nominee is subject to any disqualifications described in Rule 506(d)(1)(i) to (vii) under the Securities Act of 1933, as amended; (vii) any other information relating to such nominee that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act; (viii) a written statement from the shareholder making the recommendation stating why such recommended candidate meets the criteria and would be able to fulfill the duties of a director; and (ix) a written representation and agreement that (a) such nominee is not and will not become a party to (1) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such nominee, if elected as a director of the Company, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Company or (2) any Voting Commitment that could limit or interfere with such nominee’s ability to comply, if elected as a director of the Company, with such nominee’s fiduciary duties under applicable law, (b) such nominee is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Company with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed therein, and (c) such nominee, in such nominee’s individual capacity and on behalf of any person or entity on whose behalf the nomination is being made, would be in compliance, if elected as a director of the Company, and will comply, with all applicable corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines of the Company.

    In addition, the Nomination Notice shall set forth, as to the Person submitting the Nomination Notice, each beneficial owner, if any, on whose behalf the nomination is made and any Person acting in concert with such Persons, among other things: (i) the name and business address of such Person; (ii) the name and address of each such Person as he or she appears on the Company’s books (if he or she so appears); (iii) the class and number of shares of the Company that are owned beneficially and of record by each such Person; (iv) a description of any agreement, arrangement or understanding with respect to the nomination between or among such Persons, any of their respective affiliates or associates, and any others acting in concert with any of the foregoing; (v) a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, warrants, convertible securities, stock appreciation or similar rights, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of such written notice by, or on behalf of, each such Person, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of, each such Person, with respect to securities of the Company; (vi) a representation that the Person submitting the Nomination Notice is a holder of record of stock of the Company entitled to vote at such meeting, will so remain at the time of such meeting, and intends to appear in person or by proxy at the meeting to make such nomination; (vii) a representation whether any such Person intends or is part of a group which intends (a) to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Company’s outstanding capital stock required to elect each nominee or (b) otherwise to

     


     

    solicit proxies from shareholders in support of such nomination; and (viii) any other information relating to such shareholder and such beneficial owner, if any, required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for the election of directors in an election contest pursuant to Section 14(a) of the Exchange Act.

    The information required by clauses (iii), (iv) and (v) above shall be updated by the Person delivering such Nomination Notice and each beneficial owner, if any, on whose behalf the Nomination Notice is being submitted not later than ten days after the record date for the meeting to disclose such information as of the record date. The Company may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility or qualification of such proposed nominee to serve as a director of the Company. A written consent to being named in a proxy statement as a nominee, and to serve as a director if elected, signed by each nominee, shall be filed with any Nomination Notice.

    If the presiding officer at any shareholders’ meeting determines that a nomination was not made in accordance with the procedures prescribed by the Bylaws, the presiding officer will so declare to the meeting and the defective nomination will be disregarded.

    Notice Deadlines. Nomination Notices and Shareholder Proposals in connection with an annual meeting shall be delivered to the Company’s Corporate Secretary at the principal executive office not less than 90 nor more than 120 calendar days before the first anniversary of the date of the Company’s notice of annual meeting sent to shareholders in connection with the previous year’s annual meeting; provided that if no annual meeting was held in the previous year, or the date of the annual meeting has been established to be more than 30 calendar days earlier than, or 60 calendar days after, the anniversary of the previous year’s annual meeting, notice by a shareholder, to be timely, must be so received not later than: (i) the 90th day prior to the annual meeting; or (ii) if later, the close of business on the 10th day following the day on which public announcement is first made of the date of the annual meeting. Nomination Notices in connection with a special meeting at which directors are to be elected shall be delivered to the Company’s Secretary at the principal executive office not later than the close of business on: (i) the 90th day prior to such special meeting; or (ii) if later, the 10th day following the day on which public announcement is first made of the date of the special meeting and of the fact that directors are to be elected at such meeting.

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit Number Description

     

     

    3(ii)

    Amendment No. 1 to Bylaws of SunLink Health Systems, Inc.

    104

    Cover Page Interactive Data File - The cover page XBRL tags are embedded within the Inline XBRL document.

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    SUNLINK HEALTH SYSTEMS, INC.

    Date:

    May 23, 2024

    /s/ Mark J. Stockslager.

    Mark J. Stockslager.

    Chief Financial Officer

     

     

     


    Get the next $SSY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SSY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SSY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Turner Howard E bought $968 worth of shares (1,000 units at $0.97), increasing direct ownership by 0.49% to 205,785 units (SEC Form 4)

    4 - SUNLINK HEALTH SYSTEMS INC (0000096793) (Issuer)

    11/28/23 3:17:47 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    $SSY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SSY
    SEC Filings

    View All

    $SSY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Regional Health Properties, Inc. and SunLink Health Systems, Inc. Announce Receipt of Shareholder Approvals for Merger

    Regional Health Properties, Inc. ("Regional") (OTCQB:RHEP) (OTCQB:RHEPA) and SunLink Health Systems, Inc. ("SunLink") (NYSE:SSY) jointly announced today that, at special meetings of their respective shareholders each held on August 4, 2025, Regional shareholders and SunLink shareholders approved the merger of SunLink with and into Regional, with Regional as the surviving corporation pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of April 14, 2025, as amended, by and between Regional and SunLink. The SunLink shareholders also approved at their special meeting, on a non-binding advisory basis, the SunLink merger-related compensation proposal. The closing of the pr

    8/4/25 6:11:00 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    Regional Health Properties, Inc. and SunLink Health Systems, Inc. Announce Receipt of Shareholder Approvals for Merger

    Atlanta, GA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. ("Regional") (OTCQB:RHEP) (OTCQB:RHEPA) and SunLink Health Systems, Inc. ("SunLink") (NYSE:SSY) jointly announced today that, at special meetings of their respective shareholders each held on August 4, 2025, Regional shareholders and SunLink shareholders approved the merger of SunLink with and into Regional, with Regional as the surviving corporation pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of April 14, 2025, as amended, by and between Regional and SunLink. The SunLink shareholders also approved at their special meeting, on a non-binding advisory basis, the SunLink merger-rela

    8/4/25 5:30:00 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    SunLink Health Systems, Inc. Adjourns Special Meeting Until August 4, 2025 and Urges Stockholders of Record as of June 20, 2025 to Vote FOR the Proposed Merger With Regional Health Properties, Inc. by August 3, 2025 at 11:59 PM EDT

    SunLink Health Systems, Inc. ("SunLink") (NYSE:SSY) today announced that SunLink convened its special meeting (the "Special Meeting") of the holders of its common stock (the "Common Stock") on July 29, 2029, and the holders of the Common Stock approved the adjournment of the Special Meeting. The Special Meeting will reconvene on Monday, August 4, 2025, at 10:00 a.m., Eastern Time, at Hyatt House Hotel, 3595 Cumberland Blvd., Atlanta, Georgia 30339. The record date for determination of the holders of the Common Stock entitled to notice of, and to vote at, the reconvened Special Meeting remains the close of business on June 20, 2025. Any proxies previously submitted by the holders of the Co

    7/29/25 4:34:00 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    SEC Form 15-12G filed by SunLink Health Systems Inc.

    15-12G - SUNLINK HEALTH SYSTEMS INC (0000096793) (Filer)

    8/26/25 5:17:45 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    SEC Form S-8 POS filed by SunLink Health Systems Inc.

    S-8 POS - SUNLINK HEALTH SYSTEMS INC (0000096793) (Filer)

    8/14/25 5:20:59 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    SEC Form S-8 POS filed by SunLink Health Systems Inc.

    S-8 POS - SUNLINK HEALTH SYSTEMS INC (0000096793) (Filer)

    8/14/25 5:20:19 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    Former Director Ford C Michael returned 49,422 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - SUNLINK HEALTH SYSTEMS INC (0000096793) (Issuer)

    8/14/25 6:30:44 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    SEC Form 4 filed by Former VP of SSY, & CEO of Sub Brockman Sheila G.

    4 - SUNLINK HEALTH SYSTEMS INC (0000096793) (Issuer)

    8/14/25 6:19:23 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    Former Director Burleson Gene E returned 91,601 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - SUNLINK HEALTH SYSTEMS INC (0000096793) (Issuer)

    8/14/25 6:14:44 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    $SSY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by SunLink Health Systems Inc. (Amendment)

    SC 13D/A - SUNLINK HEALTH SYSTEMS INC (0000096793) (Subject)

    11/13/23 5:26:31 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13D/A filed by SunLink Health Systems Inc. (Amendment)

    SC 13D/A - SUNLINK HEALTH SYSTEMS INC (0000096793) (Subject)

    7/24/23 5:26:50 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13D/A filed by SunLink Health Systems, Inc. (Amendment)

    SC 13D/A - SUNLINK HEALTH SYSTEMS INC (0000096793) (Subject)

    5/24/21 3:48:59 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    $SSY
    Financials

    Live finance-specific insights

    View All

    SunLink Health Systems, Inc. Provides Update on Special Cash Dividend Scheduled to Be Paid Prior to SunLink's Proposed Merger with Regional Health Properties, Inc.

    SunLink Health Systems, Inc. (NYSE:SSY) today issued the following update with respect to its scheduled $0.10 per share special cash dividend approved by SunLink's Board of Directors and previously announced on July 18, 2025 (the "Special Cash Dividend"). SunLink understands that trades of SunLink common stock entered into during the period (the "due bill period") beginning July 29, 2025 (the record date for the Special Cash Dividend) and through July 30, 2025 (the payment date for the Special Cash Dividend) will have a due bill attached for the Special Cash Dividend. Due bills obligate sellers to deliver the Special Cash Dividend to the buyer. This means that persons who purchase SunLink

    7/24/25 1:03:00 PM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    SunLink Health Systems, Inc Declares Special Cash Dividend Prior to with the Proposed Merger with Regional Health Properties, Inc.

    SunLink Health Systems, Inc. (NYSE:SSY) today announced that its Board of Directors has declared a special cash dividend (the "Special Cash Dividend") prior to the previously announced proposed merger (the "Merger") with Regional Health Properties, Inc. ("Regional") pursuant to the Amended and Restated Agreement and Plan of Merger, dated April 14, 2025, as amended (the "Merger Agreement"). The Special Cash Dividend will be $0.10 per share, payable in cash to the stockholders of record as of July 29, 2025. The aggregate estimated payment for the Special Cash Dividend is expected to be approximately $704,600, based on 7,040,603 shares of SunLink's common stock outstanding as of June 20, 2025.

    7/21/25 9:01:00 AM ET
    $SSY
    Hospital/Nursing Management
    Health Care

    REGIONAL HEALTH PROPERTIES AND SUNLINK HEALTH SYSTEMS REVISE ALL-STOCK MERGER TRANSACTION

    Atlanta, GA, April 15, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. ("Regional") (OTCQB:RHEP) (OTCQB:RHEPA) and SunLink Health Systems, Inc. ("SunLink") (NYSE:SSY) jointly announced today that they have entered into an amended and restated agreement and plan of merger (the "merger agreement"), pursuant to which SunLink will merge with and into Regional (the "merger") in exchange for the issuance of an aggregate of approximately 1,595,401 shares of Regional common stock and 1,408,121 shares of Regional's newly-authorized Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares (the "Regional Series D Preferred Stock") with an initial liquidation preference o

    4/15/25 8:00:00 AM ET
    $SSY
    Hospital/Nursing Management
    Health Care